The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Financial analysis of Incyte's Q4 earnings, future growth potential, and stock rating with a 34% upside potential to ...

On January 7, 2025, the US Food and Drug Administration (FDA) issued two parallel guidance documents for the Section 503A and Section 503B bulk ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...

The first Nutrition Facts Label regulations were published in 1993 and launched in 1994. More than two decades later, in 2016, the U.S. Food and Drug Administration (FDA ... of public health concern ...

You should also review our Publishing Platform Guidelines. Together we can make ... please report it to us. Combined with our automated defenses, these reports help us identify and prevent abuse.

Changes to the FDA labeling guidance in support of FALCPA include alterations to the definitions of “major” food allergens ...